In the United States over 24 million people are affected with diabetes at a cost of over $170 Billion annually. Each year about 1.6 million new diabetes cases are diagnosed in adults. In approximately 20% of diabetic patients, the disease reaches a stage where serious complications develop and begin to progress, including the loss of feeling in the hands and feet, persistent wounds, many forms of pain, poor sleep, low energy, eyesight degradation, and the loss of kidney and heart function. Patients who have developed these complications do not see their conditions relieved by beginning or continuing tight control of their blood sugar with drugs and subcutaneous shots. In these patients, the disease will continue to progress which is why diabetes is the leading cause of blindness, kidney failure, heart disease and amputations. The prognosis for people with advanced diabetic complications has been quite dim, until now.
The Artificial Pancreas Treatment (APT) represents a major shift in the approach to treating advanced diabetes complications. APT is an intravenous therapy, administered in a clinical setting, that utilizes a precise high-pressure pulsation algorithm to intelligently perfuse insulin into a diabetic patient- effectively mimicking the effect that a normal pancreas has on the liver. The therapy stimulates the liver to produce critical metabolic enzymes otherwise absent or dramatically reduced in both type 1 and type 2 diabetics. Rather than working to control blood sugar, the APT treats an advanced diabetic’s metabolic disorder by restoring their ability to properly convert carbohydrates into cellular energy. Because the onset and progression of advanced diabetes complications are due primarily to a patient’s inability to use carbohydrates for cellular energy, the APT re-opens a critical pathway for a healthier metabolism—tissues heal, and the serious complications from advanced diabetes are halted or reversed.